SLC6A3 and Alzheimer disease: While hallucinations in AD predict the coincidence of DLB with a specificity of 100% [4], the presence of non-motor symptoms, decreased dopamine transporter imaging [5] and response to dopaminergic therapy does not help to separate DLB from PD since only about 36% of subjects can be clinically classified as ‘responders’ using the L-dopa challenge [6],[7].